Author
Listed:
- Jing-Wen Shih
(Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
Research Center of Cancer Translational Medicine, Taipei Medical University
Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University
Comprehensive Cancer Center, University of California at Davis)
- Wei-Fan Chiang
(Chi-Mei Medical Center, Liouying
School of Dentistry, National Yang-Ming University)
- Alexander T. H. Wu
(Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University
Graduate Institute of Medical Science, National Defense Medical Center)
- Ming-Heng Wu
(Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University)
- Ling-Yu Wang
(Comprehensive Cancer Center, University of California at Davis)
- Yen-Ling Yu
(Institute of Molecular and Genomic Medicine, National Health Research Institutes)
- Yu-Wen Hung
(Institute of Molecular and Genomic Medicine, National Health Research Institutes)
- Wen-Chang Wang
(Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University)
- Cheng-Ying Chu
(Research Center of Cancer Translational Medicine, Taipei Medical University)
- Chiu-Lien Hung
(Comprehensive Cancer Center, University of California at Davis)
- Chun A. Changou
(Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University
Comprehensive Cancer Center, University of California at Davis
Core Facility Center, Office of R&D, Taipei Medical University)
- Yun Yen
(Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University)
- Hsing-Jien Kung
(Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
Research Center of Cancer Translational Medicine, Taipei Medical University
Comprehensive Cancer Center, University of California at Davis
Institute of Molecular and Genomic Medicine, National Health Research Institutes)
Abstract
Long noncoding RNAs (lncRNAs) have been implicated in hypoxia/HIF-1-associated cancer progression through largely unknown mechanisms. Here we identify MIR31HG as a hypoxia-inducible lncRNA and therefore we name it LncHIFCAR (long noncoding HIF-1α co-activating RNA); we describe its oncogenic role as a HIF-1α co-activator that regulates the HIF-1 transcriptional network, crucial for cancer development. Extensive analyses of clinical data indicate LncHIFCAR level is substantially upregulated in oral carcinoma, significantly associated with poor clinical outcomes and representing an independent prognostic predictor. Overexpression of LncHIFCAR induces pseudo-hypoxic gene signature, whereas knockdown of LncHIFCAR impairs the hypoxia-induced HIF-1α transactivation, sphere-forming ability, metabolic shift and metastatic potential in vitro and in vivo. Mechanistically, LncHIFCAR forms a complex with HIF-1α via direct binding and facilitates the recruitment of HIF-1α and p300 cofactor to the target promoters. Our results uncover an lncRNA-mediated mechanism for HIF-1 activation and establish the clinical values of LncHIFCAR in prognosis and potential therapeutic strategy for oral carcinoma.
Suggested Citation
Jing-Wen Shih & Wei-Fan Chiang & Alexander T. H. Wu & Ming-Heng Wu & Ling-Yu Wang & Yen-Ling Yu & Yu-Wen Hung & Wen-Chang Wang & Cheng-Ying Chu & Chiu-Lien Hung & Chun A. Changou & Yun Yen & Hsing-Jie, 2017.
"Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1α co-activator driving oral cancer progression,"
Nature Communications, Nature, vol. 8(1), pages 1-16, August.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms15874
DOI: 10.1038/ncomms15874
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms15874. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.